NEW ENEMA TREATMENTS FOR INFLAMMATORY BOWEL-DISEASE

[1] HANAUER SB, 1986, GASTROENTEROLOGY, V90, P1449

[2] TIXOCORTOL PIVALATE, A CORTICOSTEROID WITH NO SYSTEMIC GLUCOCORTICOID EFFECT AFTER ORAL, INTRARECTAL, AND INTRANASAL APPLICATION [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (03) : 343 - 350

[3] LEVINSON RA, 1985, RECENT DEV THERAPY I

[4] INHIBITION OF CYTOTOXICITY BY SULFASALAZINE .1. SULFASALAZINE INHIBITS SPONTANEOUS CELL-MEDIATED CYTOTOXICITY BY PERIPHERAL-BLOOD AND INTESTINAL MONONUCLEAR-CELLS FROM CONTROL AND INFLAMMATORY BOWEL-DISEASE PATIENTS [J]. IMMUNOPHARMACOLOGY, 1986, 11 (02): : 101 - 109

[5] PEPPERCORN MA, 1984, ANN INTERN MED, V3, P377

[6] SCHRODER H, 1972, CLIN PHARMACOL THER, V13, P539

[7] SULFASALAZINE-INDUCED EXACERBATION OF ULCERATIVE-COLITIS [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (07) : 409 - 412

[8] INHIBITION OF CYTOTOXICITY BY SULFASALAZINE .2. SULFASALAZINE AND SULFAPYRIDINE INHIBIT DIFFERENT STAGES OF THE NK AND NKCF LYTIC PROCESSES [J]. IMMUNOPHARMACOLOGY, 1986, 11 (02): : 111 - 118

[9] STENSON WF, 1984, VIEWPOINTS DIG DIS, V16, P13

[10] VANHEES PAM, 1980, GUT, V21, P532

[1] HANAUER SB, 1986, GASTROENTEROLOGY, V90, P1449

[2] TIXOCORTOL PIVALATE, A CORTICOSTEROID WITH NO SYSTEMIC GLUCOCORTICOID EFFECT AFTER ORAL, INTRARECTAL, AND INTRANASAL APPLICATION [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1983, 33 (03) : 343 - 350

[3] LEVINSON RA, 1985, RECENT DEV THERAPY I

[4] INHIBITION OF CYTOTOXICITY BY SULFASALAZINE .1. SULFASALAZINE INHIBITS SPONTANEOUS CELL-MEDIATED CYTOTOXICITY BY PERIPHERAL-BLOOD AND INTESTINAL MONONUCLEAR-CELLS FROM CONTROL AND INFLAMMATORY BOWEL-DISEASE PATIENTS [J]. IMMUNOPHARMACOLOGY, 1986, 11 (02): : 101 - 109

[5] PEPPERCORN MA, 1984, ANN INTERN MED, V3, P377

[6] SCHRODER H, 1972, CLIN PHARMACOL THER, V13, P539

[7] SULFASALAZINE-INDUCED EXACERBATION OF ULCERATIVE-COLITIS [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (07) : 409 - 412

[8] INHIBITION OF CYTOTOXICITY BY SULFASALAZINE .2. SULFASALAZINE AND SULFAPYRIDINE INHIBIT DIFFERENT STAGES OF THE NK AND NKCF LYTIC PROCESSES [J]. IMMUNOPHARMACOLOGY, 1986, 11 (02): : 111 - 118

[9] STENSON WF, 1984, VIEWPOINTS DIG DIS, V16, P13

[10] VANHEES PAM, 1980, GUT, V21, P532